Neuritek Therapeutics is dedicated to develop breakthrough treatments for PTSD.
Neuritek's team dedicates passion, experience
and knowledge to treatment development in PTSD.
Leadership Team
William E. Hapworth M.D.
, President & Chairman of the Board
Dr. Hapworth has over 30 years psychiatry experience, and has treated more than 150K patients. He built the largest psychiatric practice in NYC and has been the Principal Investigator in numerous industry and investigator-initiated clinical trials. He has also been an Assistant Clinical Professor at NYU for over 25 years. Full bio →
Allan Bradley, Interim CEO / CFO & Director
Mr. Bradley has over 16 years of C level experience. He is a M&A, regulatory, strategic, capital and capital markets expert. Allan has managed international finance and operations teams and sits on the board of directors for two technology companies and a public oil and gas corporation. Full bio →
Chirag B. Raval, PhD, Chief Medical Officer
Dr. Raval has expertise in tissue engineering and membrane transport as both a chemical (B.ChE) and biomedical (MS, PhD) engineer. Dr. Raval utilizes an interdisciplinary mindset to establish new mechanisms of action across various psychiatric conditions. C.B. has produced value in the field via biotechnology commercialization, peer-reviewed research papers and crafting op-ed pieces supporting wellness and longevity. Full bio →
Margaret Courtney, PhD, Director of Pharmaceutical Development
Dr. Courtney has over twenty years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialization. She has worked in small and large pharmaceutical companies and following on from her doctoral studies has developed specific expertise in drug delivery systems.
Board of Directors
Dr. William E. Hapworth M.D.
, President & Chairman of the Board
Dr. Hapworth has over 30 years psychiatry experience, and has treated more than 150K patients. He built the largest psychiatric practice in NYC and has been the Principal Investigator in numerous industry and investigator-initiated clinical trials. He has also been an Assistant Clinical Professor at NYU for over 25 years.
Allan Bradley
, Interim CEO / CFO & Director
Mr. Bradley has over 16 years of C level experience. He is a M&A, regulatory, strategic, capital and capital markets expert. Allan has managed international finance and operations teams and sits on the board of directors for two technology companies and a public oil and gas corporation.
Neuritek’s vision is to bring next-generation psychiatric therapies to market for people suffering from psychiatric disorders, focusing initially on PTSD.
Neuritek Therapeutics is a biopharmaceutical company committed to developing revolutionary treatments with the potential to transform the lives of patients and families suffering from psychiatric disorders.
Built on years of research and clinical care of patients with PTSD, our goal is to develop the first mechanism-based treatment for PTSD. We do this through rigorous basic and clinical science, innovative research methodologies, and highly efficient clinical trial operations.
Novel treatment development for PTSD has been declared a priority by the Institute of Medicine, the United States Department of Defense, and the United States Department of Veterans Affairs.